Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | $16.50 | Buy | Lake Street |
| 7/16/2024 | $9.00 → $12.00 | Hold → Buy | Stifel |
| 11/28/2023 | $11.00 | Hold | Stifel |
| 8/4/2023 | $20.00 → $200.00 | Strong Buy → Outperform | Raymond James |
| 3/21/2023 | $5.50 → $10.00 | Buy → Hold | Jefferies |
| 3/7/2022 | $28.00 → $14.00 | Outperform | Cowen & Co. |
| 2/22/2022 | $28.00 → $23.00 | Strong Buy → Outperform | Raymond James |
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp
TORONTO, May 15, 2024 /CNW/ - Profound Medical Corp. (TSX:PRN) (NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2024 revenue growth of 108% over Q4-2023.During the fourth quarter, Profound made two key executive changes to fur
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2024 Results Conference Call Details: Date: Thursday, March 6, 2025 Time: 4:30 p.m. ET Live Call Registration: https://
8-K - Profound Medical Corp. (0001628808) (Filer)
10-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05
TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association's ("AUA") Annual Meeting. The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) and is scheduled to conclude at approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern T
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host a hybrid (in-person and virtual) investor event on Monday, April 28, 2025, during the American Urological Association's ("AUA") Annual Meeting in Las Vegas, NV, from 3:30 p.m. to 5:00 p.m. Pacific Time (6:30 p.m. to 8:00 p.m. Eastern Time). "The program will feature presentations from members of Profound's management team as well as by leading physicians on: (1) TULSA-PRO® and its unrivalled flexibility to treat a wide
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50
Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously
Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00